Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma

Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma

Ovarian clear cell carcinoma (OCCC) is a histological subtype of ovarian cancer that is more frequent in Asian countries (~25% of ovarian cancers) than in US/European countries (less than 10%). OCCC is refractory to conventional platinum-based chemotherapy, which is effective against high-grade sero...

Full description

Bibliographic Details
Main Authors:	Kazuaki Takahashi, Masataka Takenaka, Aikou Okamoto, David D. L. Bowtell, Takashi Kohno
Format:	Article
Language:	English
Published:	MDPI AG 2021-04-01
Series:	Cancers
Subjects:	ovarian clear cell carcinoma ARID1A synthetic lethality gemcitabine molecular targeted therapy precision medicine
Online Access:	https://www.mdpi.com/2072-6694/13/8/1769

Similar Items

<i>CCNE1</i> Is a Putative Therapeutic Target for <i>ARID1A</i>-Mutated Ovarian Clear Cell Carcinoma
by: Naoki Kawahara, et al.
Published: (2021-05-01)

ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma
by: Emi Sato, et al.
Published: (2018-06-01)

Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report
by: Yu-Chien Lin, et al.
Published: (2020-12-01)

Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer
by: Yew Chung Tang, et al.
Published: (2018-03-01)

Clinicopathological Significance of Loss of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma
by: Ie-Ming Shih, et al.
Published: (2010-12-01)

Mismatch repair deficiency is associated with specific morphologic features and frequent loss of ARID1A expression in ovarian clear cell carcinoma
by: Huijuan Ge, et al.
Published: (2021-02-01)

Survival Outcomes Between Clear Cell and Non-Clear Cell Epithelial Ovarian Cancer
by: Wasanai Jermsirisakpong, et al.
Published: (2013-03-01)

Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma
by: Saira Khalique, et al.
Published: (2021-07-01)

LOSS OF ARID 1A PROTEIN EXPRESSION IN OVARIAN ENDOMETRIOMAS AS A PROBABLE PREDISPOSITION TO DEVELOPMENT OF ENDOMETRIOSIS-ASSOCIATED OVARIAN CARCINOMAS
by: Tihomir Totev, et al.
Published: (2019-07-01)

The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression?
by: Shouying Xu, et al.
Published: (2021-10-01)

Treatment results and prognostic factors of clear cell ovarian carcinomas and ovarian carcinomas with clear cell component
by: M. D. Ahmedova, et al.
Published: (2014-07-01)

Antioxidants and Therapeutic Targets in Ovarian Clear Cell Carcinoma
by: Tsukuru Amano, et al.
Published: (2021-01-01)

Therapeutic applications of PARP inhibitors in ovarian cancer
by: Hongyu Xie, et al.
Published: (2020-07-01)

Establishment and molecular characterization of a human ovarian clear cell carcinoma cell line (FDOV1)
by: Wei Jiang, et al.
Published: (2018-07-01)

Molecular determinants of sensitivity to poly(ADP-ribose) polymerase inhibitors in epithelial ovarian cancer
by: O'Connor, Kevin William
Published: (2016)

Two cases of clear cell ovarian cancer in young patients
by: Mahdieh Rajabi-Moghaddam, et al.
Published: (2016-07-01)

Ovarian endometrioid carcinoma and clear cell carcinoma: A 21-year retrospective study
by: Ling Zhou, et al.
Published: (2021-05-01)

Defective cell cycle checkpoints as targets for anti-cancer therapies
by: Brian eGabrielli, et al.
Published: (2012-02-01)

Genomic characterization of Chinese ovarian clear cell carcinoma identifies driver genes by whole exome sequencing
by: Qin Yang, et al.
Published: (2020-09-01)

ARID1A Mutations and PI3K/AKT Pathway Alterations in Endometriosis and Endometriosis-Associated Ovarian Carcinomas
by: Patrick Imesch, et al.
Published: (2013-09-01)

Transcriptome Analysis of Ovarian and Uterine Clear Cell Malignancies
by: Jill Alldredge, et al.
Published: (2020-12-01)

Hepatocyte nuclear factor-1β (HNF-1β) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma
by: Okamoto, Takako
Published: (2014)

FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers
by: Katia A. Mesquita, et al.
Published: (2021-04-01)

Current Position of the Molecular Therapeutic Targets for Ovarian Clear Cell Carcinoma: A Literature Review
by: Tsukuru Amano, et al.
Published: (2019-07-01)

Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer
by: Minchul Kim, et al.
Published: (2016-09-01)

Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma
by: Tashbib Khan, et al.
Published: (2020-04-01)

Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study
by: Chenchen Zhu, et al.
Published: (2021-03-01)

Clear cell/endometrioid type ovarian carcinoma associated with endometriosis of the ipsilateral ovary
by: Rudić-Biljić-Erski Ivana, et al.
Published: (2019-01-01)

Nodal induces apoptosis and inhibits proliferation in ovarian endometriosis-clear cell carcinoma lesions
by: Rinako Miura, et al.
Published: (2019-04-01)

Identification of potential key genes associated with ovarian clear cell carcinoma
by: Xu Y, et al.
Published: (2018-11-01)

The pathomorphological characteristics of clear-cell adenocarcinomas of the ovary and its mixed tumors with a clear-cell component
by: M.. D Akhmedova, et al.
Published: (2014-07-01)

A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
by: Shoji Nagao, et al.
Published: (2020-02-01)

Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma
by: Huimei Zhou, et al.
Published: (2020-04-01)

The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells
by: Silvana eDe Lorenzo, et al.
Published: (2013-09-01)

Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1
by: Tahira Baloch, et al.
Published: (2019-01-01)

Primary Laparoscopic Surgery Does Not Affect the Prognosis of Early-Stage Ovarian Clear Cell Cancer
by: Yin S, et al.
Published: (2021-08-01)

Endometriosis does not confer improved prognosis in ovarian clear cell carcinoma: a retrospective study at a single institute
by: Ting Zhao, et al.
Published: (2018-06-01)

Recurrence Patterns and Survival Outcomes in Chinese Patients with Surgically Treated Recurrent Ovarian Clear Cell Carcinoma: A Single Institutional Analysis of 45 Cases
by: Ye S, et al.
Published: (2020-02-01)

Extracellular miRNAs as Predictive Biomarkers for Glypican-3-Derived Peptide Vaccine Therapy Response in Ovarian Clear Cell Carcinoma
by: Mayu Ukai, et al.
Published: (2021-02-01)

Endometriosis-associated ovarian cancer
by: S. A. Levakov, et al.
Published: (2017-02-01)